Cerebellum differential expression analysis of genotype by time effects in Pax6 mice and controls. This set contains genes for which there is an additive effect of the mutation and linear increase in both mutant and wild types through time.
Using a two-stage process, several genes were initially identified using microarray analyses of cerebellar tissue from ethanol-treated PKCgamma mutant and wild-type mice. This geneset consists of genes related to PKCgamma mutant expression changes due to chronic ethanol diet.
Authors:
Bowers BJ, Radcliffe RA, Smith AM, Miyamoto-Ditmon J, Wehner JM
Studies involving use of chronic nicotine treatment identify unique nicotine addiction genes and the biological processes they control in C3H/HeJ and C57BL/6J mice. The studies are done in five brain regions, amygdale (Amyg), hippocampus (HP), nucleus accumbens (NA), prefrontal cortex (PFC) and ventral tegmental area (VTA). Results are obtained using gene expression profiling via cDNA microarrays and gene ontology. This gene set comprises 36 genes that are corregulated within each of the five brain regions in both C3H/HeJ and C57BL/6J mice.
Authors:
Wang J, Gutala R, Hwang YY, Kim JM, Konu O, Ma JZ, Li MD
This gene set comprises 399 genes that are differentially expressed within each of five brain regions (amygdale, hippocampus, nucleus accumbens, prefrontal cortex and ventral tegmental area) when chronic nicotine treatment is administered to C3H/HeJ mice only. Background: Studies involving use of chronic nicotine treatment identify unique nicotine addiction genes and the biological processes they control in B6 and C3 mice. Results are obtained using gene expression profiling and gene ontology.
Authors:
Wang J, Gutala R, Hwang YY, Kim JM, Konu O, Ma JZ, Li MD
This gene set comprises 239 genes that are differentially expressed within each of five brain regions (amygdala, hippocampus, nucleus accumbens, prefrontal cortex and ventral tegmental area) when chronic nicotine treatment is administered to C57BL/6J mice only. Background: Studies involving use of chronic nicotine treatment identify unique nicotine addiction genes and the biological processes they control in B6 and C3 mice. Results are obtained using gene expression profiling and gene ontology.
Authors:
Wang J, Gutala R, Hwang YY, Kim JM, Konu O, Ma JZ, Li MD
This gene set comprises 25 genes that are downregulated within each of five brain regions (amygdale (Amyg), hippocampus (HP), nucleus accumbens (NA), prefrontal cortex (PFC) and ventral tegmental area (VTA)) when chronic nicotine treatment is administered to C57BL/6J mice only. Background: Studies involving use of chronic nicotine treatment identify unique nicotine addiction genes and the biological processes they mediate in C3H/HeJ and C57BL/6J mice. Results are obtained using gene expression profiling via cDNA microarrays and gene ontology.
Authors:
Wang J, Gutala R, Hwang YY, Kim JM, Konu O, Ma JZ, Li MD
This gene set comprises 66 genes that are upregulated within each of five brain regions (amygdale, hippocampus, nucleus accumbens, prefrontal cortex and ventral tegmental area) when chronic nicotine treatment is administered to B6 mice only. Background: Studies involving chronic nicotine treatment identify unique nicotine addiction genes and the biological processes they mediate in C3 and B6 mice. Results are obtained using gene expression profiling via cDNA microarrays and gene ontology.
Authors:
Wang J, Gutala R, Hwang YY, Kim JM, Konu O, Ma JZ, Li MD
This gene set comprises 85 genes that are upregulated within each of three overrepresented brain regions (nucleus accumbens (NA), prefrontal cortex (PFC) and ventral tegmental area (VTA)) when chronic nicotine treatment is administered to C3H/HeJ mice only. Background: Studies involving use of chronic nicotine treatment identify unique nicotine addiction genes and their resultant biological processes in C3H/HeJ and C57BL/6J mice. The entire study is done in five brain regions, amygdale (Amyg), hippocampus (HP), nucleus accumbens (NA), prefrontal cortex (PFC) and ventral tegmental area (VTA). Results are obtained using gene expression profiling via cDNA microarrays and gene ontology.
Authors:
Wang J, Gutala R, Hwang YY, Kim JM, Konu O, Ma JZ, Li MD
By analyzing Genome-Wide Association data of successful vs. unsuccessful nicotine-abstinent participants in independent clinical trials from 3 centers, study replicates quit-success genes. To conduct the study, three cohorts were used. Sample 1 consisting of subjects who received a double-blinded placebo-controlled trial of bupropion hydrochloride and a trial of NRT. Sample 2 consisted of subjects who were used in the trial of the clinical effectiveness of NRT. Sample 3 consisted of subjects who were used in the trial of the clinical effectiveness of bupropion hydrochloride.
Authors:
Uhl GR, Liu QR, Drgon T, Johnson C, Walther D, Rose JE, David SP, Niaura R, Lerman C
Genome-wide association studies are conducted of two human cohorts, one group demonstrating nicotine dependence and another successfully quitting smoking. Study shows that some genetic components associated with the ability to quit overlap while many do not overlap. To perform the study, DNA samples were obtained from NIH volunteers and the allelic frequencies of the samples were analyzed using Affymetrix array analysis. This gene set comprises 290 genes associated with nicotine dependence.
Authors:
Drgon T, Montoya I, Johnson C, Liu QR, Walther D, Hamer D, Uhl GR
Study shows that PKC-gamma wild-type mice develop tolerance to the sedative- hypnotic effects of ethanol after chronic ethanol treatment but mutant mice do not, making these genotypes a suitable model for identifying changes in gene expression related developing tolerance toward ethanol. This gene set comprises 27 ethanol- dependence genes that were upregulated in the PKC-gamma wild-type mice during the experiment.
Authors:
Bowers BJ, Radcliffe RA, Smith AM, Miyamoto-Ditmon J, Wehner JM
Striatum Gene Expression Correlates for COCA_TIME_COND_CHG measured in BXD RI Males obtained using GeneNetwork Striatum M430V2 (Apr05) RMA. The COCA_TIME_COND_CHG measures Cocaine CPP - difference in time spent relative to baseline drug exposure under the domain Cocaine. The correlates were thresholded at a p-value of less than 0.001.
Authors:
Philip VM, Duvvuru S, Gomero B, Ansah TA, Blaha CD, Cook MN, Hamre KM, Lariviere WR, Matthews DB, Mittleman G, Goldowitz D, Chesler EJ
Striatum Gene Expression Correlates for COCA_TIME_PCT_CHANGE measured in BXD RI Males obtained using GeneNetwork Striatum M430V2 (Apr05) RMA. The COCA_TIME_PCT_CHANGE measures Cocaine CPP - difference in percent test time spent relative to preconditioning under the domain Cocaine. The correlates were thresholded at a p-value of less than 0.001.
Authors:
Philip VM, Duvvuru S, Gomero B, Ansah TA, Blaha CD, Cook MN, Hamre KM, Lariviere WR, Matthews DB, Mittleman G, Goldowitz D, Chesler EJ
Hippocampus Gene Expression Correlates for LM_PAIR1 measured in BXD RI Males obtained using GeneNetwork Hippocampus Consortium M430v2 (Jun06) RMA. The LM_PAIR1 measures Activity during 1st tone shock pairing under the domain Basal Behavior. The correlates were thresholded at a p-value of less than 0.001.
Authors:
Philip VM, Duvvuru S, Gomero B, Ansah TA, Blaha CD, Cook MN, Hamre KM, Lariviere WR, Matthews DB, Mittleman G, Goldowitz D, Chesler EJ
Cerebellum Gene Expression Correlates for SPD_TIMEDOWEL0SEC measured in BXD RI Females & Males obtained using SJUT Cerebellum mRNA M430 (Mar05) RMA. The SPD_TIMEDOWEL0SEC measures Dowel Test - Time 0 Sec under the domain Porsolt. The correlates were thresholded at a p-value of less than 0.001.
Authors:
Philip VM, Duvvuru S, Gomero B, Ansah TA, Blaha CD, Cook MN, Hamre KM, Lariviere WR, Matthews DB, Mittleman G, Goldowitz D, Chesler EJ
These genes are a 1 class SAM significant (1% FDR) in nucleus accumbens (core + shell) for saline treated ("basal") control vs. Fyn KO mice. The list was filtered for an average Sscore >2.0 or <-2.0. Data from Farris and Miles, PLoS One, 2013.
QTL for morphine preference on Chr10 at D10MIT282 (24.33 Mbp , Build 37)
Description:
morphine preference spans 0.00 - 49.33 Mbp (NCBI Build 37) on Chr10. This interval was obtained by using an interval width of 25 Mbp around the peak marker (Build 37, MGI, http://informatics.jax.org).
Authors:
Berrettini WH, Ferraro TN, Alexander RC, Buchberg AM, Vogel WH
QTL for alcohol preference locus on Chr10 at D10Mit126 (39.43 Mbp , Build 37)
Description:
alcohol preference locus spans 14.43 - 64.43 Mbp (NCBI Build 37) on Chr10. This interval was obtained by using an interval width of 25 Mbp around the peak marker (Build 37, MGI, http://informatics.jax.org).
QTL for alcohol preference locus on Chr10 at D10Mit126 (39.43 Mbp , Build 37)
Description:
alcohol preference locus spans 14.43 - 64.43 Mbp (NCBI Build 37) on Chr10. This interval was obtained by using an interval width of 25 Mbp around the peak marker (Build 37, MGI, http://informatics.jax.org).
GeneWeaver